Join        Login             Stock Quote

FDA Stops Pediatric Trials Of Amgen's (AMGN) Sensipar After Death

 February 26, 2013 01:24 PM

(By Balachander) The U.S. Food and Drug Administration (FDA) has stopped all pediatric clinical trials of Amgen Inc.'s (NASDAQ: AMGN) Sensipar after the death of a 14-year-old patient in a trial.

Sensipar is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.

The U.S. health regulator said it continues to gather information on the circumstances surrounding the patient's death. The FDA said it has not  concluded whether or not Sensipar had a role in the death.

"This communication is intended to inform health care professionals that we are evaluating the information and will communicate our final conclusions and recommendations when our review is complete," the FDA said in a statement.

[Related -Amgen, Inc. (NASDAQ:AMGN): What Will Drive Amgen This Year?]

The FDA has approved Sensipar, which lowers calcium levels in the blood, for use in adults in 2004. Clinical trials were conducted to determine if the drug is effective and can be used safely in children (less than 18 years of age).

"Amgen is working as rapidly as possible to understand the circumstances of what happened," Bloomberg reported quoting an e-mail from Amgen spokeswoman Ashleigh Koss.

Amgen generated sales of $950 million from Sensipar last year, according to a Bloomberg data.

Amgen shares traded 0.06 percent lower at $89.52 at 1.22 pm ET on Tuesday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.